Uganda is poised to adopt Lenacapavir, a groundbreaking HIV prevention method, following promising results from Gilead Sciences’ PURPOSE 1 trial. The trial, conducted in Uganda and South Africa, demonstrated 100% effectiveness in preventing HIV transmission among women and adolescent girls.

Read More >>>>>https://highflyerreport.com/2024/08/23/a-new-dawnworld-anticipates-gileads-lenacapavir-rollout/